Interleukin-2 plus ribavirin versus interferon-α-2b plus ribavirin in patients with chronic hepatitis C who did not respond to previous interferon-α-2b treatment

• Published in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy Vol. 18; no. 6; p. 407
• Main Authors: Malaguarnera, Mariano, Pistone, Giovanni, Neri, Sergio, Romano, Marcello, Brogna, Alfio, Musumeci, Salvatore
• Format: Journal Article
• Language: English
• Published: Wolters Kluwer Health, Inc 01.11.2004

Background: Interferon (IFN)-α-2b therapy has been shown to improve clinical conditions of patients with chronic hepatitis C. Several studies showed that the addition of ribavirin to IFNα-2b greatly improved the biochemical as well as the virologic and histological response rate in patients with chr...